Sciclone Pharmaceuticals, Inc. (SCLN) Tops Q2 EPS by 3c
Tweet
Share
E-mailGet Alerts SCLN Hot Sheet
Join SI Premium – FREE
Sciclone Pharmaceuticals, Inc. (NASDAQ: SCLN) reported Q2 EPS of $0.13, $0.03 better than the analyst estimate of $0.10. Revenue for the quarter came in at $33.1 million versus the consensus estimate of $33.36 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
- Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
